COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360… Dec 1, 2021
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 Nov 9, 2021
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360… Nov 9, 2021
MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd. Oct 7, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104 Sep 9, 2021